## UNITED STATES SECURITIES AND EXCHANGE COMMISSION April 4, 2017

## ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES EXCHANGE ACT OF 1934

Q BioMed, Inc.

## File No.0-55535 CF#34623

\_\_\_\_\_

Q BioMed, Inc. submitted an application under Rule 24b-2 requesting confidential treatment for information it excluded from the Exhibits to a Form 10-Q filed on October 17, 2016, as amended.

Based on representations by Q BioMed, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibits will not be released to the public for the time periods specified:

Exhibit	10.1	through	September 6, 2021
Exhibit	10.2	through	September 6, 2021

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Brent J. Fields Secretary